Treatment Approach for This 77-Year-Old with Elevated PSA and Gleason 6 Disease
This patient requires definitive treatment with external beam radiotherapy plus androgen deprivation therapy (ADT) for 2-3 years, not active surveillance or watchful waiting, due to the markedly elevated PSA of 22 ng/mL which reclassifies him as high-risk disease despite the Gleason 6 score.
Risk Stratification is Critical
This case illustrates a common pitfall: focusing solely on Gleason score while ignoring PSA level. While the Gleason 6 (3+3) histology appears favorable, the PSA of 22 ng/mL automatically places this patient in the high-risk category regardless of Gleason score 1. The guidelines are explicit that low-risk disease requires PSA <10 ng/mL, Gleason ≤6, AND clinical stage T1-2b 1.
Key Clinical Features:
- PSA 22 ng/mL (>10 = high risk)
- Gleason 6 (3+3) in 4/14 cores (increased from 2/12 previously)
- Focal high-grade PIN in 3/12 cores
- Age 77 years
- Disease progression evident (2/12 cores → 4/14 cores)
Recommended Treatment Algorithm
Step 1: Complete Staging Workup
Before treatment, this patient requires:
- Bone scintigraphy - mandatory given PSA >10 ng/mL 1
- Pelvic imaging (MRI or CT) to assess nodal involvement
- Full blood count, alkaline phosphatase, creatinine 1
- Digital rectal examination for clinical T-staging
Step 2: Primary Treatment Selection
External beam radiotherapy is the preferred definitive treatment for this 77-year-old patient with high-risk features 1:
Radiation dose: Minimum 70-78 Gy using 3D conformal or IMRT techniques 2
- Conventional fractionation: 1.8-2.0 Gy per fraction over 6-7 weeks
- Alternative: Moderate hypofractionation (60 Gy/20 fractions or 70 Gy/28 fractions) 3
Combined with ADT:
Why NOT Active Surveillance or Watchful Waiting?
Active surveillance is contraindicated in this patient for multiple reasons:
- PSA 22 ng/mL excludes him from surveillance protocols - guidelines specify PSA must be <10 ng/mL for low-risk disease 2, 3
- Evidence of progression - increased core involvement (2/12 → 4/14 cores)
- Age 77 with likely >5-10 year life expectancy - patients >75 years with Gleason ≥6 and PSA ≥10 ng/mL should NOT defer treatment 4
- High-risk patients have better survival with active intervention than observation 2
Why NOT Radical Prostatectomy?
While technically an option, radiation therapy is preferred at age 77 because:
- Equivalent oncologic outcomes to surgery in this risk category
- Lower perioperative morbidity in elderly patients
- Better preservation of quality of life
- Surgery typically reserved for younger patients with >10 year life expectancy 1
Critical Pitfalls to Avoid
Do not be misled by the Gleason 6 designation alone. The PSA of 22 ng/mL is the dominant risk factor here. A study specifically addressing elderly patients demonstrated that those >75 years with PSA ≥10 ng/mL and Gleason ≥6 should receive definitive treatment, not deferred therapy 4.
The high-grade PIN finding is a red flag - while not cancer itself, it indicates increased risk and supports the need for aggressive management 5. The progression from 2 to 4 positive cores further confirms active disease requiring intervention.
Regarding ADT duration: While guidelines note uncertainty about optimal timing (ranging 3 months to 3 years in trials), the evidence for high-risk disease supports 2-3 years of total ADT 1, 2, 3. Consider prophylactic breast irradiation (8-15 Gy in 1-3 fractions) 1-2 weeks before starting antiandrogen therapy to prevent painful gynecomastia 1.
Follow-Up Protocol
After completing radiotherapy: